newsfilter
← Latest News
Business Wire·

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF’4404) Pfizer Inc.